SCHEMBL3047798

SCHEMBL3047798

CC1(C)CCC(NCc2ccc(-c3ccc4[nH]cnc4c3)cc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.42
MEN1 O00255 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CXCR4 P61073 1/20 0.37
OPRM1 P35372 3/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36
OPRL1 P41146 2/20 0.35
QPCT Q16769 2/20 0.35
KDM4E B2RXH2 1/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
PRKD1 Q15139 1/20 0.33
HDAC1 Q13547 1/20 0.33
TNIK Q9UKE5 1/20 0.33
ABCB1 P08183 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13136949 0.91 QPCT (0.43) HRH3MEN1RAB9AKMT2ACYP3A4
Trifluoroacetic Acid SCHEMBL3041840 0.90 CCR2 (0.38) HRH3MEN1RAB9AKMT2AOPRM1
SCHEMBL13137079 0.90 MAP4K4 (0.41) MEN1RAB9AKMT2AOPRM1OPRL1
Hydrochloric Acid SCHEMBL3040204 0.89 MAP4K4 (0.41) MEN1RAB9AKMT2AOPRM1OPRL1
SCHEMBL13137146 0.89 FLT3 (0.34) HRH3MEN1RAB9AKMT2ACYP3A4
Hydrochloric Acid SCHEMBL3050507 0.88 MEN1 (0.34) HRH3MEN1RAB9AKMT2ACYP3A4
SCHEMBL13137127 0.87 CHEK1 (0.35) HRH3CYP3A4CYP2D6CXCR4OPRM1
SCHEMBL13137267 0.87 DHODH (0.33) CYP3A4CYP2D6CXCR4QPCT
SCHEMBL13137162 0.87 HDAC1 (0.39) CYP3A4OPRM1OPRD1OPRK1QPCT
Hydrochloric Acid SCHEMBL3048045 0.87 CHEK1 (0.34) HRH3MEN1RAB9AKMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222345-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION 2010-09-02 US claimed
EP-2049481-A2 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SmithKline Beecham Corporation (US) 2009-04-22 EP claimed
WO-2008021851-A2 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION (US) 2008-02-21 WO claimed
US-20100222345-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION 2010-09-02 US disclosed
EP-2049481-A2 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SmithKline Beecham Corporation (US) 2009-04-22 EP disclosed
WO-2008021851-A2 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION (US) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222345-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS OPRL1, OPRM1, OPRK1 HRH3 406/4885MEN1 4829/4885RAB9A 1469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.